Hbm9161 dose b    (DrugBank: -)

1 disease
告示番号疾患名(ページ内リンク)臨床試験数
63特発性血小板減少性紫斑病1

63. 特発性血小板減少性紫斑病 [臨床試験数:311,薬物数:185(DrugBank:39),標的遺伝子数:43,標的パスウェイ数:132
Searched query = "Idiopathic thrombocytopenic purpura", "Primary immune thrombocytopenia"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.
1 / 311 trial found
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT04428255
(ClinicalTrials.gov)
July 21, 20209/6/2020A Clinical Study on the Efficacy and Safety of HBM9161 in Patients With ITPA Randomized, Double-blind, Placebo-controlled, Phase 2/3 Operational Seamless Designed Clinical Study to Evaluate the Efficacy and Safety of HBM9161 Weekly Subcutaneous Injection in Patients With Primary Immune ThrombocytopeniaPrimary Immune Thrombocytopenic PurpuraDrug: HBM9161 Dose A;Drug: HBM9161 Dose B;Drug: PlaceboHarbour BioMed (Guangzhou) Co. Ltd.NULLNot yet recruiting18 YearsN/AAll36Phase 2;Phase 3China